Can deploying trained laypeople working directly with low income adults with asthma in the community improve outcomes? This is what the Home-Based Asthma Support and Education (HomeBASE) trial set out to answer.1 While comprehensive evidence-based guidelines and effective pharmacotherapies exist, there are still 3,345 asthma-associated deaths and 1.8 million emergency department (ED) visits each year.2,3 There is clearly a disconnect between optimal asthma therapy... Read More
Current cholesterol guidelines promote the use of statins as first line therapy in primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) events. Despite the impressive risk reduction associated with statins, a 60% to 80% residual risk of vascular events remains. Does adding niacin to statin treatment reduce residual risk? Or does statin therapy alone offer optimal benefit?
Primary prevention trials of statins have shown they can reduce the... Read More
Achieving provider status has been the latest buzz for many pharmacy organizations over the past year. Provider status will likely lead to increased access to pharmacists' services in the ambulatory care setting and inclusion of medication therapy management by pharmacists as an essential benefit in emerging healthcare delivery models. Arguably the most important goal in achieving provider status is payment for pharmacists' patient care services under Medicare Part B. The key to... Read More